- Home
- MRNS vs IPA Comparison
MRNS vs IPA Comparison
Compare MRNS & IPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNS
- IPA
- Stock Information
- Founded
- MRNS 2003
- IPA 1983
- Country
- MRNS United States
- IPA Canada
- Employees
- MRNS N/A
- IPA N/A
- Industry
- MRNS Biotechnology: Pharmaceutical Preparations
- IPA Biotechnology: Pharmaceutical Preparations
- Sector
- MRNS Health Care
- IPA Health Care
- Exchange
- MRNS Nasdaq
- IPA Nasdaq
- Market Cap
- MRNS 19.0M
- IPA 18.9M
- IPO Year
- MRNS 2014
- IPA 2017
- Fundamental
- Price
- MRNS $0.30
- IPA $0.44
- Analyst Decision
- MRNS Buy
- IPA Strong Buy
- Analyst Count
- MRNS 12
- IPA 2
- Target Price
- MRNS $4.28
- IPA $6.00
- AVG Volume (30 Days)
- MRNS 6.6M
- IPA 1.1M
- Earning Date
- MRNS 11-12-2024
- IPA 12-12-2024
- Dividend Yield
- MRNS N/A
- IPA N/A
- EPS Growth
- MRNS N/A
- IPA N/A
- EPS
- MRNS N/A
- IPA N/A
- Revenue
- MRNS $31,466,000.00
- IPA $17,441,886.00
- Revenue This Year
- MRNS $20.74
- IPA $4.33
- Revenue Next Year
- MRNS $32.38
- IPA $35.64
- P/E Ratio
- MRNS N/A
- IPA N/A
- Revenue Growth
- MRNS 1.63
- IPA 11.21
- 52 Week Low
- MRNS $0.26
- IPA $0.35
- 52 Week High
- MRNS $11.26
- IPA $2.60
- Technical
- Relative Strength Index (RSI)
- MRNS 25.07
- IPA 40.98
- Support Level
- MRNS $0.29
- IPA $0.40
- Resistance Level
- MRNS $0.37
- IPA $0.53
- Average True Range (ATR)
- MRNS 0.04
- IPA 0.07
- MACD
- MRNS 0.02
- IPA 0.00
- Stochastic Oscillator
- MRNS 17.95
- IPA 37.76
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a supplier of custom antibodies to the research industry and industrial community. The company has aggregated its operations into one reportable segment, Antibody Production, and Related Services. It operates in three principal geographical areas - the United States of America, Canada, Europe, Australia and others. The majority of its revenue is derived from United States of America.